Genmab A/S - Company Announcement
02/10/2007 21:10
PR Newswire
COPENHAGEN, October 2 /PRNewswire/ --
- Roche Files CTA for Third Genmab Antibody
- Summary: Genmab's Partner Roche has Filed a CTA With the British
MHRA for a Genmab Antibody.
Genmab A/S (OMX: GEN) announced today that its partner Roche has filed a
Clinical Trial Application (CTA) with the British Medicines and Healthcare
products Regulatory Agency (MHRA) for a Genmab antibody developed under the
companies' collaboration. Genmab will receive a milestone payment from Roche
which does not influence Genmab's financial guidance for 2007.
Under the agreement with Roche, Genmab utilizes its broad antibody
expertise and development capabilities to create human antibodies to a broad
range of disease targets identified by Roche. Genmab receives milestone and
royalty payments based on successful products. In certain circumstances,
Genmab may obtain rights to develop products based on disease targets
identified by Roche. If all goals are reached, the value of the collaboration
to Genmab could be USD 100 million, plus royalties.
"We are pleased that the third antibody created by Genmab under our
partnership with Roche is entering the clinic and to now have eight products
in clinical development," said Lisa N. Drakeman, Ph.D., Chief Executive
Officer of Genmab. "Genmab has now achieved the eleventh milestone under the
collaboration."
About Genmab A/S
Genmab is a leading international biotechnology company focused on
developing fully human antibody therapeutics for unmet medical needs. Using
unique, cutting-edge antibody technology, Genmab's world class discovery and
development teams have created and developed an extensive pipeline of
products for potential treatment of a variety of diseases including cancer
and autoimmune disorders. As Genmab advances towards a commercial future, we
remain committed to our primary goal of improving the lives of patients who
are in urgent need of new treatment options. For more information on Genmab's
products and technology, visit http://www.genmab.com.
This press release contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar
expressions identify forward looking statements. Actual results or
performance may differ materially from any future results or performance
expressed or implied by such statements. The important factors that could
cause our actual results or performance to differ materially include, among
others, risks associated with product discovery and development,
uncertainties related to the outcome and conduct of clinical trials including
unforeseen safety issues, uncertainties related to product manufacturing, the
lack of market acceptance of our products, our inability to manage growth,
the competitive environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. Genmab
is not under an obligation to up-date statements regarding the future
following the publication of this release; nor to confirm such statements in
relation to actual results, unless this is required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R);
HuMax-CD20(R); HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-TAC(TM);
HuMax-HepC(TM); HuMax-CD38(TM); HuMax-ZP3(TM); and UniBody(TM) are all
trademarks of Genmab A/S.
Stock Exchange Release no. 46/2007
Contact:
Helle Husted
Sr. Director
Investor Relations
T: +45-33-44-7730
M: +45-25-27-47-13
E: hth@genmab.com
Contact: Helle Husted, Sr. Director, Investor Relations, T: +45-33-44-7730, M: +45-25-27-47-13, E: hth@genmab.com